RxDoctor Payments Data

Sam Hansen, MD

Cardiovascular Disease · Lafayette, INNPI 1154397701

Payments from drug & device makers

$1,436in general payments, 2019–2025

Across 46 payments — averaging $31.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$415
  • Pfizer$253
  • Amgen$221
  • Novartis$125
  • Boehringer Ingelheim$101
  • AstraZeneca$85
  • plus $236 from 7 others

What the payments were for

  • Food & beverage$1,436100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,436 in reported general payments places this provider in the 35th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$246,148
Medicare patients
1,060
Services billed
3,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban836$865,781
XareltoRivaroxaban379$462,726
EntrestoSacubitril/Valsartan192$210,329
JardianceEmpagliflozin40$44,998
Repatha SureclickEvolocumab43$39,230
NexlizetBempedoic Acid/Ezetimibe20$16,928
Dabigatran EtexilateDabigatran Etexilate Mesylate48$16,508
Nifedipine ErNifedipine562$14,932
FarxigaDapagliflozin Propanediol18$14,707
Breo ElliptaFluticasone/Vilanterol23$10,291
Rosuvastatin Calcium859$9,773
Metoprolol Succinate768$8,983
BrilintaTicagrelor15$8,197
Atorvastatin Calcium762$5,479
Labetalol Hcl206$4,622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$253$865,781836 claims
Johnson & JohnsonXarelto$415$462,726379 claims
NovartisEntresto$125$210,329192 claims
Boehringer IngelheimJardiance$101$44,99840 claims
AstraZenecaFarxiga, Brilinta$85$22,90433 claims
GSKBreo Ellipta$35$10,29123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →